



**/ immatics launches Phase I clinical study on cancer vaccine IMA901 /
Only 22 months after the first round of funding /**

Tübingen, Germany, November 29th, 2005. immatics biotechnologies GmbH, a leader in the development of peptide-based immunotherapeutic substances for the treatment of cancers, announces the beginning of a Phase I clinical study on its product candidate IMA901. Under the study, some two dozen patients suffering from advanced stages of renal cell cancer will be treated in six locations in Germany, the United Kingdom and Switzerland. “With this study, we will be determining the immunoefficacy and compatibility of our new vaccine, thus laying the groundwork for a more far-reaching Phase II study,” explains immatics Chief Medical Officer Jürgen Frisch.

CSO Harpreet Singh stresses the short preclinical study phase, saying: “We are launching this study only 22 months after the successful conclusion of our first round of funding, and are convinced that we’ll also be able to make rapid progress in the clinical environment.” It typically takes a number of years before a company’s first product candidate can enter clinical development. In the case of immatics, it was only at the beginning of 2004 that a consortium under the lead of 3i and Wellington Partners had invested a total of € 14.1 million in the company.

The swift pace of development stems from immatics’ unrivaled technological platform for quickly identifying and validating hundreds of suitable peptide antigens, so-called TUMAPs (tumor-associated peptides) from human tumor tissue. IMA901, for example, consists of 11 different peptide antigens, which are all found in the majority of renal cell cancer patients. This is likely to dramatically increase the probability that these antigens will be able to sensitize the human immune system against the tumor tissue, thus activating the body’s own defensive mechanisms. “Up until now, we haven’t had any effective therapeutic approaches for combating renal cell cancer. We have high hopes for our new immunotherapeutic substance IMA901. That’s why our clinic, together with an international network of further experienced hospitals, is attaching top priority to the development of this highly

30 promising substance,” explains Prof. Arnulf Stenzl from the Tübingen Urological
Clinic, which was selected to serve as the lead center for the study.

For immatics, the clinical study on IMA901 represents the first step in the
development of new products. Having its own development platform enables the
company to swiftly identify and validate further potential immunotherapeutic
35 substances for combating cancers, such as pancreatic or colorectal cancers. “I
don’t currently know of any other biotech company that has so swiftly taken its first
product candidate into clinical development and that additionally possesses this
kind of potential for further candidates,” notes Thomas Widmann, the Chairman of
the Supervisory Board of immatics and a co-founder of Swiss-based
40 biopharmaceutical company Actelion.

About immatics

immatics (www.immatics.com) is an independent biopharmaceutical company that
focuses on the development of new immunotherapeutic substances for cancer therapy.
45 The product candidates from immatics are based upon tumor-associated peptides
(TUMAPs) that specifically stimulate the immune system against cancer cells. In
November 2005 – and thus only 22 months after the conclusion of its first round of
funding totaling € 14 million – the company begins an international clinical study on its
product candidate IMA901 for combating renal cell cancer. Further product candidates,
50 also consisting of peptide-based immunotherapeutic substances for cancer therapy, are
presently undergoing preclinical development and will serve as the basis for a rapidly
expanding product pipeline.

Formed in the year 2000 as a spin-off from the Institute of Immunology at the University
of Tübingen, immatics today employs a staff of more than 30 people. The members of
55 immatics’ Supervisory Board include the head of the institute, Hans-Georg
Rammensee, as well as Actelion co-founder Thomas Widmann, the former global head
of regulatory affairs at Bayer AG, Ulrich Granzer and GPC Biotech CSO Sebastian
Meier-Ewert.

60 Published by: immatics biotechnologies GmbH: Dr. Niels Emmerich, Paul-Ehrlich-Straße 15,
D-72076 Tübingen, Germany, +49 (0)7071-565125-0, emmerich@immatics.com